Sarepta Therapeutics, Inc. 10-Q — AI Bull & Bear Analysis

Sarepta's Q1 2026 filing presents a company at a crossroads, where aggressive balance sheet management is masking severe commercial and regulatory headwinds. While the transition to a leaner cost structure is a positive step toward sustainability, the collapse of ELEVIDYS sales in the non-ambulatory segment reveals a fragile dependence on a narrowing patient population. The net income beat is an accounting victory, but the operating cash flow remains negative at $202.7 million. Investors must now weigh the efficiency of the 'new' Sarepta against the reality of its regulatory risks. The ability to restore the non-ambulatory label for ELEVIDYS and resolve the ESSENCE trial fallout will be the primary drivers of long-term value. Until organic product revenue stabilizes and the litigation gauntlet is cleared, the company's profitability remains precarious and highly dependent on one-off partnership windfalls.